Studies were undertaken to examine the efficacy of combining monoclonal antibodies BA-1, BA-2, BA-3 + complement with a stabilized derivative of cyclophosphamide (mafosfamid) for elimination of leukemic cell line clonogenic cells. In a series of experiments conducted with leukemic cell lines a combination of two cycles of treatment with BA-1, 2, 3 + complement combined with 25 μg/ml-1 mafosfamid was superior to either modality alone in killing clonogenic leukemic cells. Identical treatment of normal bone marrow had no effect on the monopotent stem cells CFU-E and CFU-GM, or the pluripotent stem cell CFU-MIX, but some inhibition of the monopotent stem cell CFU-MK did occur. These results suggest that consideration be given to incorporation of BA-1, 2, 3 + complement and mafosfamid combination treatment in autologous bone marrow transplantation for acute lymphoblastic leukemia.
Bibliographical noteFunding Information:
*This work was supported by grants CA-21737, CA-31685, and CA-36725 from the National Institutes of Health, grant IM-380 from the American Cancer Society, and a grant from the Prudential Insurance Company of America. T.W.L. and D.A.V. are Scholars of the Leukemia Society of America.
- Autologous bone marrow transplantation
- monoclonal antibody + complement